Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 21 studies | 73% ± 20% | |
lung | 20 studies | 70% ± 21% | |
brain | 19 studies | 48% ± 23% | |
intestine | 14 studies | 55% ± 26% | |
eye | 10 studies | 57% ± 24% | |
kidney | 9 studies | 79% ± 14% | |
liver | 8 studies | 50% ± 24% | |
bone marrow | 7 studies | 46% ± 22% | |
heart | 7 studies | 34% ± 13% | |
lymph node | 6 studies | 63% ± 24% | |
pancreas | 5 studies | 73% ± 24% | |
placenta | 5 studies | 69% ± 33% | |
uterus | 5 studies | 86% ± 18% | |
adipose | 5 studies | 40% ± 22% | |
prostate | 5 studies | 69% ± 26% | |
skin | 4 studies | 53% ± 34% | |
breast | 4 studies | 79% ± 7% | |
adrenal gland | 3 studies | 66% ± 12% | |
esophagus | 3 studies | 78% ± 14% | |
thymus | 3 studies | 68% ± 21% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 25947.14 | 1445 / 1445 | 100% | 217.91 | 183 / 183 |
kidney | 100% | 54310.01 | 89 / 89 | 100% | 562.82 | 901 / 901 |
thymus | 100% | 40988.27 | 653 / 653 | 100% | 290.37 | 604 / 605 |
prostate | 100% | 26233.02 | 245 / 245 | 100% | 178.38 | 501 / 502 |
lung | 100% | 39950.70 | 578 / 578 | 100% | 194.83 | 1151 / 1155 |
brain | 100% | 29270.44 | 2639 / 2642 | 100% | 229.35 | 703 / 705 |
adrenal gland | 100% | 33434.53 | 258 / 258 | 99% | 258.31 | 228 / 230 |
ovary | 100% | 49391.11 | 180 / 180 | 99% | 207.25 | 424 / 430 |
breast | 100% | 35010.76 | 459 / 459 | 98% | 148.84 | 1099 / 1118 |
uterus | 100% | 33454.55 | 170 / 170 | 98% | 172.26 | 448 / 459 |
bladder | 100% | 29483.62 | 21 / 21 | 97% | 160.20 | 487 / 504 |
intestine | 100% | 21843.06 | 966 / 966 | 97% | 127.61 | 509 / 527 |
stomach | 100% | 17529.81 | 359 / 359 | 97% | 152.72 | 276 / 286 |
pancreas | 96% | 10849.47 | 314 / 328 | 99% | 204.31 | 177 / 178 |
liver | 97% | 12211.96 | 220 / 226 | 98% | 110.08 | 397 / 406 |
skin | 100% | 33124.09 | 1807 / 1809 | 93% | 122.46 | 438 / 472 |
adipose | 100% | 41407.85 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 39332.68 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 28727.17 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 163.03 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 44.50 | 1 / 1 |
heart | 99% | 25107.91 | 856 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 79.55 | 28 / 29 |
peripheral blood | 89% | 66718.63 | 830 / 929 | 0% | 0 | 0 / 0 |
muscle | 89% | 8483.93 | 714 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 70% | 53.35 | 56 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007399 | Biological process | nervous system development |
GO_0042985 | Biological process | negative regulation of amyloid precursor protein biosynthetic process |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0005615 | Cellular component | extracellular space |
GO_0010008 | Cellular component | endosome membrane |
GO_0030660 | Cellular component | Golgi-associated vesicle membrane |
GO_0000139 | Cellular component | Golgi membrane |
GO_0031090 | Cellular component | organelle membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005576 | Cellular component | extracellular region |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0016020 | Cellular component | membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0001540 | Molecular function | amyloid-beta binding |
GO_0005515 | Molecular function | protein binding |
GO_0005524 | Molecular function | ATP binding |
Gene name | ITM2B |
Protein name | Integral membrane protein 2 Integral membrane protein 2B (Immature BRI2) (imBRI2) (Protein E25B) (Transmembrane protein BRI) (Bri) [Cleaved into: BRI2, membrane form (Mature BRI2) (mBRI2); BRI2 intracellular domain (BRI2 ICD); BRI2C, soluble form; Bri23 peptide (Bri2-23) (ABri23) (C-terminal peptide) (P23 peptide)] Integral membrane protein 2B |
Synonyms | BRI BRI2 |
Description | FUNCTION: Plays a regulatory role in the processing of the amyloid-beta A4 precursor protein (APP) and acts as an inhibitor of the amyloid-beta peptide aggregation and fibrils deposition. Plays a role in the induction of neurite outgrowth. Functions as a protease inhibitor by blocking access of secretases to APP cleavage sites.; FUNCTION: Mature BRI2 (mBRI2) functions as a modulator of the amyloid-beta A4 precursor protein (APP) processing leading to a strong reduction in the secretion of secretase-processed amyloid-beta protein 40 and amyloid-beta protein 42.; FUNCTION: Bri23 peptide prevents aggregation of APP amyloid-beta protein 42 into toxic oligomers. FUNCTION: Bri23 peptide prevents aggregation of APP amyloid-beta protein 42 into toxic oligomers. .; FUNCTION: Mature BRI2 (mBRI2) functions as a modulator of the amyloid-beta A4 precursor protein (APP) processing leading to a strong reduction in the secretion of secretase-processed amyloid-beta protein 40 and amyloid-beta protein 42. .; FUNCTION: Plays a regulatory role in the processing of the amyloid-beta A4 precursor protein (APP) and acts as an inhibitor of the amyloid-beta peptide aggregation and fibrils deposition. Plays a role in the induction of neurite outgrowth. Functions as a protease inhibitor by blocking access of secretases to APP cleavage sites. . |
Accessions | ENST00000607866.1 A0A3B3IUC0 ENST00000649266.1 U3KQL7 A0A3B3ISG3 ENST00000647800.2 [Q9Y287-1] U3KQ52 ENST00000463839.3 ENST00000378549.5 [Q9Y287-2] ENST00000649452.1 ENST00000650237.1 ENST00000650479.1 A0A3B3ITP9 Q9Y287 A0A3B3IU60 |